REGENXBIO Inc (NASDAQ: RGNX) stock closed at $17.44 on 2/29/24 after a major decline of -12.4%. Moreover, this decline was accompanied by unusually high trading volume at 156% of normal. The stock has declined -5.2% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
RGNX's future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
REGENXBIO has a current Value Trend Rating of F (Lowest Rating). This rating combines highly consistent signals from two proprietary PTR measures of a stock's attractiveness. REGENXBIO has a poor Appreciation Score of 25 and a poor Power Rating of 20, and the Lowest Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.